South African Tuberculosis Vaccine Initiative (SATVI) CRS
Cape Town, Western Cape Province, South Africa
University in Cape Town
Wernher & Beit South Building, Room S 2.01, Health Sciences Faculty, OBSERVATORY, 7925 Cape Town, Anzio Rd, Observatory, Cape Town, 7935
About South African Tuberculosis Vaccine Initiative (SATVI) CRS
- Top Sponsors
- Top Collaborators
- Trials By Phase
- Recruitment Status
- Top Conditions
- Intervention Types
- Top Intervention Names
- Trials By Gender
Lead Sponsor
# Trials
Clinical Trials at South African Tuberculosis Vaccine Initiative (SATVI) CRS
During the past decade, South African Tuberculosis Vaccine Initiative (SATVI) CRS conducted 3 clinical trials. In the 10-year time frame, 3 clinical trials started and 2 clinical trials were completed, i.e. on
average, 66.7% percent of trials that started reached the finish line to date. In the past 5 years, 0 clinical trials started and 1 clinical trials were completed. i.e. 0%
of trials that started reached the finish line.
Trials List
Trail ID
Brief Title
Start Date
Completion Date
Status
Enrollment
Erlotinib Hydrochloride in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Completely Removed by Surgery (An ALCHEMIST Treatment Trial)
2014-08-18
2026-10-10
Active, not recruiting
450
Genetic Testing in Screening Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been or Will Be Removed by Surgery (The ALCHEMIST Screening Trial)
2014-08-18
Recruiting
8,300
Crizotinib in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Removed by Surgery and ALK Fusion Mutations (An ALCHEMIST Treatment Trial)
2014-08-18
2036-05-01
Recruiting
168
Dabrafenib and Trametinib Followed by Ipilimumab and Nivolumab or Ipilimumab and Nivolumab Followed by Dabrafenib and Trametinib in Treating Patients With Stage III-IV BRAFV600 Melanoma
2015-07-13
2023-10-02
Active, not recruiting
300
A Phase II/III Trial of Nivolumab, Ipilimumab, and GM-CSF in Patients With Advanced Melanoma
2015-09-10
2033-06-30
Recruiting
600
Platinum in Treating Patients With Residual Triple-Negative Breast Cancer Following Neoadjuvant Chemotherapy
2015-04-29
2031-03-29
Active, not recruiting
415
Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)
2015-08-12
2025-12-31
Active, not recruiting
6,452
Clinical Trials Sponsors and Collaborators
In terms of collaborators to trials, out of the total clinical trials conducted in "South African Tuberculosis Vaccine Initiative (SATVI) CRS"
#1 collaborator was "Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)" with 1 trials as a collaborator, "European and Developing Countries Clinical Trials Partnership (EDCTP)" with 1 trials as a collaborator, "National Institute for Medical Research, Tanzania" with 1 trials as a collaborator, "Ospedale San Raffaele" with 1 trials as a collaborator and "Otsuka Pharmaceutical Development & Commercialization, Inc." with 1 trials as a collaborator. Other collaborators include 1 different institutions and companies that were
collaborators in the rest 11 trials.
Clinical Trials Conditions at South African Tuberculosis Vaccine Initiative (SATVI) CRS
According to Clinical.Site data, the most researched conditions in "South African Tuberculosis Vaccine Initiative (SATVI) CRS" are
"Tuberculosis" (2 trials), "HIV Infections" (1 trials), "Tuberculosis, MDR" (1 trials) and "Tuberculosis, Pulmonary" (1 trials). Many other conditions were trialed in "South African Tuberculosis Vaccine Initiative (SATVI) CRS" in a lesser frequency.
Clinical Trials Intervention Types at South African Tuberculosis Vaccine Initiative (SATVI) CRS
Most popular intervention types in "South African Tuberculosis Vaccine Initiative (SATVI) CRS" are "Drug" (3 trials), "Biological" (2 trials) and "Dietary Supplement" (1 trials). Other intervention types were less common.
The name of intervention was led by "Placebo" (2 trials), "AERAS-404" (1 trials), "Bacillus Calmette-Guérin (BCG)" (1 trials), "Bedaquiline" (1 trials) and "Delamanid" (1 trials). Other intervention names were less common.
Clinical Trials Genders at South African Tuberculosis Vaccine Initiative (SATVI) CRS
The vast majority of trials in "South African Tuberculosis Vaccine Initiative (SATVI) CRS" are
4 trials for "All" genders.
Clinical Trials Status at South African Tuberculosis Vaccine Initiative (SATVI) CRS
Currently, there are NaN active trials in "South African Tuberculosis Vaccine Initiative (SATVI) CRS".
undefined are not yet recruiting,
1 are recruiting,
1 are Active, not recruiting,
and undefined are Enrolling by invitation.
In total, there were 2 completed trials in South African Tuberculosis Vaccine Initiative (SATVI) CRS,
undefined suspended trials,
and undefined terminated clinical trials to date.
Out of the total trials that were conducted in South African Tuberculosis Vaccine Initiative (SATVI) CRS, 0 "Phase 1"
clinical trials were conducted, 3 "Phase 2" clinical
trials and 1 "Phase 3" clinical trials were conducted as
well. "Phase 4" trials included 0 trials, and there were
also 0 trials that are defined as “Not Applicable".